शुभ दीपावलीDiwali offer: 3 months free on yearly plans · ends 11 NovSee plans

This filing is part of the company’s quarterly result. Read the full results article, with every figure explained →

ANUHPHRNSEAnuh Pharma Limited· Pharmaceuticals & BiotechnologyHighNeutral
Announced Wed, 20 May, 2026 · 23:48 IST

Anuh Pharma Limited has informed the Exchange regarding '66Th Annual General Meeting Will Be Held On Wednesday, 12Th August, 2026.'.

Negative operating cash flowResults View source PDFExplain this filing

ANUHPHR · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
-6.1%Reaction day
₹81.50
prior close
₹80.81
announcement price
After-mkt
timing
Nifty Microcap 250market · in no size index; the smallest one is used+1.1%-7.2% vs market
Pharmaceuticals peers, median of 160sector+0.2%-6.3% vs sector

On the reaction day the stock moved 7.2 pts less than Nifty Microcap 250 and 6.3 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
-3.5
10m
-3.5
15m
-4.3
30m
-4.6
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
-6.1+1.1-7.2+0.2-6.3
Next day
-6.2+1.2-7.4+0.2-6.4
2d
-6.3+2.8-9.1+1.5-7.8
3d
-6.1+3.5-9.7+1.4-7.6
4d
-6.1+3.5-9.6+1.6-7.7
5d
-6.1+2.8-9.0+1.0-7.2
1w
-7.5+2.8-10.3+0.4-7.9
15d
-2.5+4.2-6.7+0.7-3.2
1m
-3.2+10.1-13.3+3.1-6.3
2m
-1.4+10.0-11.4+7.2-8.6
3m
-6.3+14.6-20.8+8.2-14.4
UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 160Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Anuh Pharma Limited reported FY26 revenue of Rs. 77,165.74 Lakhs, up 16.6% from Rs. 66,151.49 Lakhs in FY25, showing solid topline growth. However, profit after tax declined 13.3% to Rs. 4,104.61 Lakhs from Rs. 4,735.19 Lakhs, while EBITDA fell to Rs. 6,607.59 Lakhs from Rs. 7,036.40 Lakhs. EBITDA margin compressed from 10.64% to 8.56%, indicating margin pressure. Operating cash flow turned negative at Rs. -301.16 Lakhs versus positive Rs. 3,712.47 Lakhs in FY25, a significant deterioration. The Board recommended a dividend of Rs. 1.50 per share (30% payout). Statutory auditors Jayantilal Thakkar & Co. issued an unmodified opinion. Nine promoter group shareholders (0.95% stake) have sought re-classification to public category. The 66th AGM is scheduled for August 12, 2026.

Likely market impact

The company shows revenue growth but declining profitability and negative operating cash flow, which may concern investors. The bonus share issuance (1:1 in July 2025) doubled share count, reducing EPS to Rs. 4.10 from Rs. 4.72. The margin compression and cash flow deterioration are red flags despite clean audit opinion.

By the numbersStandalone · Q4 FY26 vs Q4 FY25
Q4 FY26Q4 FY25Change
Revenue₹202.1 Cr₹198.1 Cr+2.0%
Operating profit₹16.77 Cr₹15.88 Cr+5.6%
Profit after tax₹11.68 Cr₹12.46 Cr−6.2%
EBITDA margin9.8%9.4%+0.4 pp

From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.